Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes?

Affiliations

¹ Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Program of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
² Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Program of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
³ Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Program of Solid Tumors, Center for Applied Medical Research, University of Navarra, Pamplona, Spain. Electronic address: igbazo@unav.es.

Free article

Editorial

Iñaki Eguren-Santamaria et al. J Thorac Oncol. 2020 Apr.

Free article

. 2020 Apr;15(4):489-492.

doi: 10.1016/j.jtho.2020.02.003.

¹ Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Program of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
² Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Program of Immunology and Immunotherapy, Center for Applied Medical Research, University of Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
³ Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Program of Solid Tumors, Center for Applied Medical Research, University of Navarra, Pamplona, Spain. Electronic address: igbazo@unav.es.

No abstract available

Comment on

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018.
Guisier F, Dubos-Arvis C, Viñas F, Doubre H, Ricordel C, Ropert S, Janicot H, Bernardi M, Fournel P, Lamy R, Pérol M, Dauba J, Gonzales G, Falchero L, Decroisette C, Assouline P, Chouaid C, Bylicki O. Guisier F, et al. J Thorac Oncol. 2020 Apr;15(4):628-636. doi: 10.1016/j.jtho.2019.12.129. Epub 2020 Jan 13. J Thorac Oncol. 2020. PMID: 31945494